Document is current

Article History

Received: 10 September 2025

Accepted: 24 December 2025

First Online: 6 January 2026

Declarations

:

: Deidentified patient samples and corresponding clinical information were obtained from patients enrolled in the WEHI-Stafford Fox Rare Cancer Program (SFRCP); all patients provided informed written consent. Ethics approval for the WEHI-SFRCP was obtained from the Royal Melbourne Hospital Human Research Ethics Committee (Project number 2015.300) and governance review by the WEHI HREC (Project number G16/02). All animal experiments were conducted according to the National Health and Medical Research Council Australian Code for the Care and Use of Animals for Scientific Purposes 8th Edition, 2013 (updated 2021), and under the approval of the WEHI Animal Ethics Committee (2019.024 and 2022.030).

: All authors have read and agreed to the published version of the manuscript.

: Eisai Inc provided drug support for this study. C.L.S. declares Advisory Boards for AstraZeneca, Clovis Oncology, Roche, Eisai Inc, Sierra Oncology, Takeda, MSD and Grant/Research support from Eisai Inc, AstraZeneca, Boehringer Ingelheim and IDEAYA Biosciences. C.JV., R.L., C.N., M.J.W. and H.E.B. report research support (paid to institution) from AstraZeneca Pty Ltd and Boehringer Ingelheim outside the submitted work. Other authors declare no conflicts of interest.